Medical devices, healthcare technology and the business of care
PMA approval · P250019

SAPIEN M3 Transcatheter Mitral Valve Replacement System

Edwards Lifesciences, LLC · Decision date Dec 22, 2025

FDA DECISIONP250019

What did the FDA approve?

FDA records P250019 as an original PMA application. The recorded decision is approval, dated Dec 22, 2025.

FDA approval order statement

Approval for the SAPIEN M3 transcatheter mitral valve replacement system. This device is indicated for the treatment of symptomatic moderate-to-severe or severe mitral regurgitation (MR) in patients who are deemed unsuitable for surgery or transcatheter edge-to-edge repair (TEER) therapy by a multidisciplinary heart team. It is also indicated for the treatment of symptomatic mitral valve dysfunction (moderate-to-severe or severe MR, severe mitral stenosis (MS), or moderate MR with moderate MS) associated with mitral annular calcification (MAC) in patients who are deemed unsuitable for surgery or TEER therapy by a multidisciplinary heart team.
Regulatory pathway
Original PMA
Clinical specialty
Cardiovascular
Decision date
Dec 22, 2025

FDA source record

Regulatory record facts

Identifier
P250019
Regulatory pathway
Premarket approval application
Product code
NPU
Decision code
APPR
Decision date
Dec 22, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Prosthesis, mitral valve, percutaneously delivered.

Product code
NPU
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P250019 received

    Application receipt date recorded by FDA.

  2. P250019 · FDA decision

    APPR

  3. P250019/S001 · Related supplement

    SAPIEN M3 Transcatheter Mitral Valve Replacement System

  4. P250019/S002 · Related supplement

    Edwards SAPIEN M3 Transcatheter Heart Valve (sizes 20mm, 23mm, 26mm, 29mm)

  5. P250019/S003 · Related supplement

    SAPIEN M3 Transcatheter Mitral Valve Replacement System

  6. P250019/S005 · Related supplement

    SAPIEN M3 Transcatheter Heart Valve (9880TFX29M)

  7. P250019/S006 · Related supplement

    Edwards SAPIEN M3 Dock (988DDS); Edwards 23F Guide Sheath (9880GS); Edwards SAPIEN M3 Crimper (9880CR); Edwards Commande

Timeline entries are records held by MedtechLedger for P250019. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P250019

Explore the linked device profile

Other records with product code NPU

Product / regulatory recordCompanyPathwayDecision dateSource
ABBOTT MEDICALPMA supplementAug 31, 2026FDA
ABBOTT MEDICALPMA supplementAug 7, 2026FDA
ABBOTT MEDICALPMA supplementOct 4, 2025FDA
ABBOTT MEDICALPMA supplementJul 29, 2025FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Edwards Lifesciences, LLC

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
One Edwards Way, Irvine, CA, 92614

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records